ArticleExperimental and therapeutic medicine2025
Predictive value of fecal sulfatide and neutrophil-to‑lymphocyte ratio in coronary heart disease.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fecal sulfatide as a non-invasive biomarker for predicting coronary heart disease.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of coronary atherosclerotic heart disease is on the rise, posing a serious threat to public health. Emerging evidence highlights the interplay between systemic inflammation and cardiovascular pathophysiology, suggesting novel diagnostic avenues. The aim of the present study was to evaluate the predictive value of fecal sulfatide and neutrophil-to-lymphocyte ratio (NLR), both individually and in combination, for coronary heart disease (CHD). A total of 523 patients diagnosed with CHD at the Cardiovascular Department of Hebei General Hospital (Shijiazhuang, China) from August 2022 to September 2023 were included in the experimental group, along with 198 healthy controls. The CHD group was further subdivided into stable angina pectoris (n=194), unstable angina pectoris (n=134), and acute myocardial infarction (AMI) groups (n=195). Fecal sulfatide and serum NLR levels were measured in both the experimental and control groups, as well as within each CHD subgroup. Multivariate logistic regression was utilized to assess whether these biomarkers serve as independent risk factors for CHD. The predictive value of fecal sulfatide and serum NLR was evaluated using receiver operating characteristic curves. Fecal sulfatide and serum NLR levels were distinctly higher in the CHD group compared with the control group (2.40±0.48 vs. 1.64±0.39 µmol/l and 2.92 vs. 1.65; P<0.05). Patients with AMI had higher NLR levels than those with stable and unstable angina pectoris (5.55 vs. 2.65 and 2.68; P<0.05). Fecal sulfatide levels were also elevated in patients with AMI (2.50±0.44 µmol/l) compared with patients with stable angina pectoris (2.32±0.48 µmol/l). Both fecal sulfatide (AUC=0.899) and NLR (AUC=0.811) exhibited strong predictive accuracy for CHD. When combined, the predictive value (AUC=0.945) was further improved. Elevated levels of fecal sulfatide and serum NLR in patients with CHD revealed that these biomarkers may serve as valuable adjuncts in the diagnosis of CHD. The combined use of these biomarkers enhances the accuracy and reliability of CHD prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.